HiSiaddi is an innovative foreign trade service provider driven by dual pillars of technology transformation and foreign trade services, operating under the "1+2+3+4=1" service system with direct access to fumaric acid supplies from multiple well-known original manufacturers.
As a foreign trade enterprise with independent R&D capabilities, HiSiaddi has conducted multiple rounds of on-site inspections of fumaric acid manufacturers through technology transformation cooperation with factories, accumulating objective and in-depth insights into different brands. It regularly analyzes fumaric acid manufacturers for clients to help select matching products. Below is a brand recommendation case study.
Contact HiSiaddi customer service for further comparative analysis of brands and models.
The buyer, NutriCare GmbH of Germany, is a leading domestic German enterprise specializing in mid-to-high-end dietary supplements and pharmaceutical intermediates, with core product lines including premium sugar-free effervescent tablets, infant chewable nutritional tablets, and ferrous fumarate APIs. Its products are sold in premium pharmacy chains DM and ROSSMANN across Germany and private medical institutions in Austria. All raw materials comply with multiple entry standards: European Pharmacopoeia (EP), FCC, EU E297 food additive specifications, LFGB, and Kosher certification, qualifying it as a refined high-volume purchaser. The enterprise previously sourced pharmaceutical-grade fumaric acid exclusively from BASF Germany. In 2025, surging European chemical raw material prices and production line maintenance at overseas factories led to uncontrollable delivery lead times, prompting the launch of localized Chinese procurement with an annual total purchase volume of 180 tons split into three specification categories: effervescent crystalline type, chewable ultrafine powder type, and high-purity powder for pharmaceutical intermediates.
After independently contacting five major domestic fumaric acid mass manufacturers for sample submission and quotation, the client became trapped in a product selection deadlock. The five mainstream mid-to-high-end manufacturers (Changmao Biotech, Yantai Hengyuan, Anhui Xuelang, Shouguang Fukang, Shanxi Hengqiang) all focused sales communication exclusively on their own product advantages, highlighting internal production capacity, pricing, and certification qualifications. None provided objective comparative analysis of competitor strengths and weaknesses, neither maliciously disparaging peers nor proactively elaborating competitor product application scenarios, indicator shortcomings, and suitable fields. German procurement engineers lacked a database of domestic fumaric acid brands, unable to distinguish between fermented and petrochemical synthetic raw materials or differences in particle size, impurities, and internal control standards across brands. Blind testing of 12 product samples in laboratories triggered three recurring defects: effervescent tablet gas expansion during storage, gritty chewable tablet texture, and excessive intermediate impurities, with cumulative sample losses exceeding 1.5 tons and product selection stagnating for nearly two months, continuously delaying new product launch schedules. Recommended by the German Chemical Raw Materials Association, the client entrusted HiSiaddi as a neutral third-party service provider to fully organize mainstream domestic brands and core product models, screening matching brands and specifications based on end-product application requirements.
HiSiaddi assembled a team of organic acid technical specialists, foreign trade compliance officers, and pharmaceutical application engineers to conduct on-site factory visits to all five leading manufacturers, review CoA quality inspection archives of each brand, and collect full-specification samples. A complete breakdown of core product lines for each brand was delivered across seven evaluation dimensions: production process (fermentation / petrochemical synthesis), impurity control, particle size classification, compliance certifications, applicable downstream scenarios, supply stability, and cost range, breaking information barriers created by manufacturers’ self-promotional sales narratives.
Core three product models: FM-U pharmaceutical crystalline grade (28–35 mesh), FM-P pharmaceutical ultrafine powder (130–150 mesh), FM-F standard food-grade crystals.
· Advantages: Pioneer of large-scale biological fermentation fumaric acid production in China; all raw materials derived from non-GMO corn saccharification liquid; full production lines under DCS automated control. Products simultaneously meet USP, EP, and FCC pharmacopoeia standards, with maleic acid stably controlled ≤0.01% and heavy metals (lead, arsenic, cadmium) <0.3ppm. Comprehensive particle size grading production lines deliver industry-leading uniform crystal regularity, making it a designated long-term supplier for premium European pharmaceutical enterprises.
· Disadvantages: Premium customized pharmaceutical-grade models carry higher quotation premiums; small-batch orders below 500kg face extended production scheduling lead times; standard food-grade models offer inferior particle size refinement compared to Shandong manufacturers.
· Suitable scenarios: Pharmaceutical intermediates, premium effervescent dietary tablets, export-grade infant food products.
Core models: HY-S food-grade crystalline fumaric acid, HY-M medium fine powder, HY-G general industrial grade.
· Advantages: Fully integrated upstream raw material industrial chain with dual parallel production lines for petrochemical and fermentation processes; China’s largest mass production capacity with abundant off-the-shelf inventory and stable bulk delivery lead times. Standard food-grade specifications cost 8%–10% less than equivalent Changmao products, with complete ISO22000 and FSSC22000 management systems.
· Disadvantages: Core off-the-shelf products focus on standard food grade; high-purity pharmaceutical ultrafine powder requires separate technical renovation scheduling. Off-the-shelf products feature broad particle size spans with insufficient narrow-range graded screening capacity, and internal control standards for trace impurities fail to meet strict EP Pharmacopoeia thresholds.
· Suitable scenarios: Mid-tier baking, beverage acidity regulators, standard feed acidifiers; unsuitable for high-end pharmaceutical intermediates.
Core models: XL-F food-grade granules, XL-P food-grade fine powder.
· Advantages: Deep expertise in domestic food ingredient markets with cost-effective fumaric acid for flour products and beverages; mainstream procurement brand for small-to-medium domestic food manufacturers with efficient domestic spot delivery and complete SC food production qualifications.
· Disadvantages: Production dominated by petrochemical synthesis processes without large-scale fermented pharmaceutical production lines; products only meet national standard food-grade limits and fail EP Pharmacopoeia impurity audits with elevated trace by-product levels.
· Suitable scenarios: Flour product preservation, standard carbonated beverages, low-end candy; incompatible with the client’s pharmaceutical-grade formulation requirements.
Core models: FK-Y pharmaceutical graded crystals (26–38 mesh), FK-F sterile ultrafine powder (140 mesh).
· Advantages: Specializes in fermented pharmaceutical-grade fumaric acid with Class 100,000 clean isolated production workshops and independent customized graded screening production lines enabling adjustable particle size ranges on demand. Maleic acid ≤0.011%, with complete Kosher and Free Sales Certificates. Custom order flexibility exceeds Changmao, with faster scheduling for small and medium batches.
· Disadvantages: Overall production capacity lower than Changmao; ultra-large orders exceeding 100 tons require batch-wise scheduling with limited single-truck off-the-shelf inventory capacity.
· Suitable scenarios: European premium dietary chewable tablets, ferrous fumarate intermediates for small and medium pharmaceutical manufacturers.
Core models: HQ standard food grade, HQ industrial grade.
· Advantages: Self-owned phthalic anhydride industrial chain delivers significant raw material cost advantages with industry-low pricing for national standard compliant products and abundant supply.
· Disadvantages: Full petrochemical synthesis production lines with no high-purity fermented product portfolio; heavy metal and ignition residue indicators only meet general domestic standards and fail EU LFGB import inspections.
· Suitable scenarios: Resin synthesis, standard feed, low-end industrial raw materials.
The client’s three core application directions: ① 28–35 mesh crystals for sugar-free effervescent tablets; ② 130–150 mesh ultrafine powder for infant chewable nutritional tablets; ③ high-purity sterile powder for ferrous fumarate pharmaceutical intermediates. HiSiaddi eliminated three brands failing EP pharmaceutical standards (Yantai Hengyuan, Xuelang, Shanxi Hengqiang), ultimately selecting two mid-to-high-end fermentation brands (Changmao Biotech and Shouguang Fukang) and three precisely matched product models, with clear explanation of selection logic and sample testing schedules provided to the client:
1. Changmao FM-U (28–35 mesh pharmaceutical crystals) → exclusively for sugar-free effervescent tablets: Fermentation process with uniform compact crystals, particles outside the target range accounting for <5% of total volume, slow controllable dissolution eliminating premature gas generation and tablet cracking during effervescent formula storage, perfectly matching the client’s acid-base ratio system for effervescent formulations;
2. Shouguang Fukang FK-F (140 mesh sterile ultrafine powder) → exclusively for infant chewable nutritional tablets: Closed low-temperature airflow pulverization plus three-stage graded screening delivers smooth powder free of coarse grains to eliminate gritty chew sensations, with moisture locked ≤0.12% to adapt to high-temperature storage conditions in Germany;
3. Changmao FM-P (135 mesh high-purity pharmaceutical fine powder) → exclusively for ferrous fumarate intermediates: Maleic acid ≤0.009%, heavy metals <0.3ppm, with CNAS testing and EP Pharmacopoeia-compliant CoA issued per batch, no abnormal peaks during chelation reactions enabling one-time passing of German pharmaceutical authority intermediate testing.
HiSiaddi simultaneously planned sample delivery sequencing: 500g laboratory samples per model → 50kg pilot samples → 1-ton mass production trial cargo shipped in three batches to NutriCare’s German R&D center.
All three rounds of sample testing fully passed all technical indicators: effervescent tablets showed no gas expansion or deformation after six months of room-temperature accelerated testing, infant chewable tablets recorded a 99.2% sensory evaluation pass rate, and ferrous fumarate intermediates exhibited no abnormal peaks in liquid chromatography analysis, completely resolving production failures caused by prior blind product selection. The client fully recognized HiSiaddi’s neutral product selection service and formally signed an annual framework procurement contract for 180 tons: 76 tons of Changmao FM-U crystals for effervescent tablets, 59 tons of Shouguang FK-F chewable powder, and 45 tons of Changmao FM-P high-purity intermediate powder. Goods were scheduled monthly in 12 staggered batches across both brands and shipped from Shanghai Port to Hamburg Port.
HiSiaddi uniformly organized full customs clearance documentation (English-German bilingual CoA, GHS-SDS, Kosher certificates, raw material traceability files) for all batches, enabling one-time customs clearance at Hamburg Port, Germany. The client’s three production lines completed full switchover to domestic raw materials, and three premium nutritional products delayed for three months entered pharmacy channels across Germany and Austria as scheduled.
In the following year of cooperation, the client expanded OEM high-end dietary businesses in Poland and the Czech Republic, placing an additional annual fumaric acid procurement order of 65 tons. All subsequent Chinese raw material brand selection and sample coordination work for organic acids were fully entrusted to HiSiaddi.
1. Neutral objective brand analysis provided by HiSiaddi eliminated three low-end/generic-grade products failing indicator standards, saving approximately 32,000 EUR in subsequent sample testing and production line debugging losses;
2. Replacement of original BASF imported raw materials with two domestic fermented brands reduced comprehensive procurement costs by 29%, eliminating supply chain risks including European raw material price surges and delayed delivery lead times;
3. A domestic fumaric acid brand classification database was established, cutting new product raw material selection cycles from an initial two months to within 15 days for future projects.
Broke the limitation of relying solely on self-operated sales for customer acquisition, securing stable export channels via this benchmark European high-end order. Leveraging this implementation case, the manufacturers successively developed long-term orders with three equivalent premium nutritional product enterprises in the Netherlands and Switzerland, lifting export volumes of pharmaceutical-grade fumaric acid by over 25% and escaping low-price homogenized competition in domestic standard food-grade fumaric acid markets.
Transcended the traditional trading model limited to profit margins from physical goods, building differentiated service capabilities covering domestic raw material brand research, neutral product selection, sample follow-up, and compliance supporting services. Supported by this benchmark German case, four additional mid-to-high-end nutritional product enterprises in Finland and Belgium engaged HiSiaddi for raw material selection cooperation, consolidating the enterprise’s niche advantage in European pharmaceutical organic acid services.
Driven by performance targets, domestic fumaric acid manufacturers prioritize promotion of their own products in market outreach. Commercial interests prevent proactive objective analysis of competitor strengths and weaknesses, leaving overseas mid-to-high-end clients lacking industry knowledge of domestic brands and prone to costly selection missteps under strict constraints of national pharmacopoeia and food regulations governing raw material processes, trace impurities, and particle size indicators. As a neutral third-party foreign trade service provider independent of any single manufacturer and free from sales guidance, HiSiaddi conducts horizontal cross-industry benchmarking of mainstream brand strengths and weaknesses based on the client’s end-product formulation and production operating conditions, delivering precise matching of suitable products. It not only enables overseas high-end clients to efficiently complete localized Chinese raw material selection and procurement but also supports premium domestic fermented fumaric acid brands to accurately enter high-end European and American markets, serving as a typical implementation model for refined chemical foreign trade transitioning from physical commodity sales to technical product selection services.
Contact HiSiaddi customer service for further comparative analysis of brands and models.
+86-13120989737 
info@hisiaddi.com 
English
![tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate](/uploads/image/20260508/tert-butyl-1s3s5s-3-carbamoyl-2-azabicyclo-310-hexane-2-carboxylate-392332-99-1.webp "tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate")
